Nanourea Poisoning Management
There is no established medical literature or clinical guidance on "nanourea" poisoning, as this substance is not recognized in toxicology databases or poisoning guidelines. Given the absence of specific evidence for this agent, management must follow general poisoning principles with immediate consultation of a regional poison control center.
Critical Initial Actions
Immediately contact your regional poison control center or medical toxicologist to identify if "nanourea" represents a known substance under a different name, a novel compound, or a misidentification 1. This consultation is the highest priority action, as specialized toxicology expertise is essential when the poisoning agent is uncertain or unfamiliar.
Simultaneous Stabilization Protocol
While awaiting toxicology consultation, implement the ABCDE approach:
Airway & Breathing
- Assess and secure airway patency
- Provide supplemental oxygen or ventilatory support as needed
- Monitor respiratory rate, depth, and oxygen saturation continuously
Circulation
- Establish IV access
- Monitor vital signs including heart rate, blood pressure, and cardiac rhythm
- Obtain 12-lead ECG to identify dysrhythmias or conduction abnormalities
Disability (Neurological Status)
- Assess level of consciousness using Glasgow Coma Scale
- Check pupil size and reactivity
- Evaluate for seizure activity or abnormal movements
Exposure
- Remove contaminated clothing if dermal exposure suspected
- Perform complete physical examination looking for:
- Signs of specific toxidromes (sympathomimetic, anticholinergic, cholinergic, opioid, sedative-hypnotic)
- Skin findings (burns, cyanosis, diaphoresis)
- Odors that may suggest specific toxins
Diagnostic Workup
Obtain immediately:
- Electrolyte panel (looking for anion gap, osmolar gap)
- Renal function (creatinine, BUN)
- Serum osmolarity
- Arterial or venous blood gas (assess acid-base status, lactate)
- Glucose level
- Urinalysis
- Acetaminophen and salicylate levels (common co-ingestants)
- ECG (QRS widening, QT prolongation, dysrhythmias)
Decontamination Considerations
Do NOT administer activated charcoal or perform gastric lavage until the substance is identified and confirmed to be appropriate for these interventions. Without knowing the chemical properties of "nanourea":
- Unknown if it's adsorbed by activated charcoal
- Unknown if it causes corrosive injury (contraindication to lavage)
- Unknown absorption kinetics
Common Pitfalls to Avoid
- Never delay supportive care while attempting to identify the toxin
- Do not assume the patient's history is accurate - obtain collateral information from family, EMS, pill bottles, or witnesses
- Do not administer empiric antidotes without clear indication, as they may worsen outcomes
- Do not discharge the patient until the substance is identified and its toxicokinetic profile understood - delayed toxicity may occur with sustained-release formulations or substances requiring metabolic activation
Monitoring Requirements
Admit for continuous monitoring if:
- Any vital sign abnormality
- Altered mental status
- Intentional ingestion (suicide risk assessment needed)
- Unknown quantity ingested
- Substance identity unconfirmed
The absence of "nanourea" in standard toxicology references 1, 2 suggests this may be a novel compound, agricultural chemical, industrial substance, or misidentified agent requiring expert consultation for appropriate management.